company background image
SAGE

Sage Therapeutics NasdaqGM:SAGE Stock Report

Last Price

US$20.08

Market Cap

US$1.2b

7D

-3.6%

1Y

-51.3%

Updated

03 Oct, 2023

Data

Company Financials +

Sage Therapeutics, Inc.

NasdaqGM:SAGE Stock Report

Mkt Cap: US$1.2b

SAGE Stock Overview

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines.

SAGE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Sage Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sage Therapeutics
Historical stock prices
Current Share PriceUS$20.08
52 Week HighUS$59.99
52 Week LowUS$16.52
Beta1.14
1 Month Change-1.04%
3 Month Change-57.40%
1 Year Change-51.30%
3 Year Change-68.68%
5 Year Change-84.26%
Change since IPO-33.07%

Recent News & Updates

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Aug 09
Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Recent updates

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Aug 09
Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Feb 22
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Nov 12
An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Oct 14
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Aug 02

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics: Well-Funded But Uninspiring Data

Mar 24

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Feb 26
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics: Biogen's Backing May See It Through

Jan 04

What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

Aug 05
What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns

Jul 25

Sage Therapeutics Needs To Show Improved Data To Regain Investor Trust

Jul 12

Sage Therapeutics Q1 2021 Earnings Preview

May 03

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Feb 26
Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Sage Therapeutics names new chief executive

Dec 16

Sage Therapeutics' Deal With Biogen Should Revive It

Dec 11

Need To Know: Analysts Are Much More Bullish On Sage Therapeutics, Inc. (NASDAQ:SAGE)

Dec 11
Need To Know: Analysts Are Much More Bullish On Sage Therapeutics, Inc. (NASDAQ:SAGE)

Positive catalysts for Sage Therapeutics called out by Oppenheimer

Nov 19

Sage Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Sage Therapeutics Q3 Earnings Preview

Nov 04

Shareholder Returns

SAGEUS BiotechsUS Market
7D-3.6%-1.4%-1.1%
1Y-51.3%6.2%14.1%

Return vs Industry: SAGE underperformed the US Biotechs industry which returned 6.2% over the past year.

Return vs Market: SAGE underperformed the US Market which returned 14.1% over the past year.

Price Volatility

Is SAGE's price volatile compared to industry and market?
SAGE volatility
SAGE Average Weekly Movement17.3%
Biotechs Industry Average Movement9.1%
Market Average Movement5.5%
10% most volatile stocks in US Market14.1%
10% least volatile stocks in US Market2.6%

Stable Share Price: SAGE is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: SAGE's weekly volatility has increased from 10% to 17% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010689Barry Greenehttps://www.sagerx.com

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain.

Sage Therapeutics, Inc. Fundamentals Summary

How do Sage Therapeutics's earnings and revenue compare to its market cap?
SAGE fundamental statistics
Market CapUS$1.18b
Earnings (TTM)-US$591.62m
Revenue (TTM)US$10.37m

115.9x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SAGE income statement (TTM)
RevenueUS$10.37m
Cost of RevenueUS$361.60m
Gross Profit-US$351.22m
Other ExpensesUS$240.40m
Earnings-US$591.62m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-9.88
Gross Margin-3,386.28%
Net Profit Margin-5,704.03%
Debt/Equity Ratio0%

How did SAGE perform over the long term?

See historical performance and comparison